Second‐line therapies after treatment with fludarabine, cyclophosphamide, and rituximab (FCR) or fludarabine and cyclophosphamid alone (FC) for chronic lymphocytic leukemia (CLL) within the CLL8‐protocol of the German CLL Study Group (GCLLSG)

Catégorie Primary study
JournalBlood
Year 2011

Cet article est inclus dans 1 Systematic review Systematic reviews (1 reference)

This article is part of the following publication threads:
Loading references information
Cet article n'a pas de résumé
Epistemonikos ID: 9c74568e915fe49ca47bffe4cbc148fe252a1957
First added on: Oct 13, 2018